Havana, Aug 30. -A unique Cuban medicine will be the highlight of the Habana 2010 International Biotechnology Congress – HEBERPROT-P, a successful treatment for diabetic foot ulcers.
Registered in Cuba since 2006, HERBERPROT-P has helped some 10,000 patients in Cuba, Venezuela, Algeria and Argentina, and now will be part of discussions on the comprehensive treatment of that condition during the October 20-22 congress.
In addition, symposiums will be held on the molecular biology of epidermal growth factor and its pharmacogenomics, Luis Herrera, president of the eventâ�Ös organizing committee, told the National News Agency (AIN).
HEBERPROT-P is a product based on recombinant human growth factor which allows ulcers to heal and reduces the need for amputations in most cases.
Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in western Havana, HEBERPROT-P is used in a dozen nations and is one of the essential medications used to treat Cuban patients, Herrera said.
Diabetic foot ulcers are one of the complications with the worst medical evolution and with the most expenses involved in health care worldwide, the CIGB director commented. (Prensa Latina)